Q32 Bio (QTTB)

• Market cap: $47.7M
• 1 day: -3.48%
• 5 days: 1.31%
• 1 month: 21.25%
• 3 months: 40.58%
• 6 months: 87.44%
• Year to date: 12.79%
• 1 year: 19.02%
• 5 years: -98.27%
• 10 years: -98.84%
• Sector: Healthcare
• Industry: Biotechnology

About: Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.

Employees: 26